Corbus Pharmaceuticals (NASDAQ:CRBP) reported disappointing topline results from its Phase 2b trial of lenabasum for the treatment of cystic fibrosis.
Patients were randomized to receive either 5 mg or 20 mg of lenabasum, or placebo, twice daily. While lenabasum had a favorable safety profile and was well-tolerated, the 28-week study did not meet its primary endpoint of reducing the rate of pulmonary exacerbations.
“We are very disappointed that the study did not meet the primary endpoint,” Dr. Barbara White, Corbus’ CMO and head of research, said in a statement. She added that the topline data will be presented at the upcoming virtual North American cystic fibrosis conference.
